 | Elderly: A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.
Leuk Lymphoma. 2008 May;49(5):924-31. PMID: 18464112
The response rate to COP-X was similar to that expected with
CHOP, with low cardiac toxicity. The high rate of infectious
complications suggests that the DaunoXome dose used may be too
high for this patient group. These results support further
investigation of this regimen in patients with aggressive NHL.
|
| Outcomes:
R-CHOP-14 in patients with DLBCL
younger than 70 years: a multicentre, prospective study. Abstract
After therapy, 58 patients (73%) achieved CR-CRu (95% CI:
55-90%). With a median follow-up of 26 months, progression-free
survival (PFS) and overall survival (OS) at 30 months were 72% and
86%, respectively. Administration of R-CHOP-14 is feasible and
effective in patients <70 years.
|
| Review: Gemcitabine in the
treatment of Hodgkin lymphoma - Abstract
2008
|
| Big news: Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Blood. 2008 Apr 29. PMID: 18445689
These findings demonstrate that the prognostic value of the
6-gene model remains significant in the era of R-CHOP treatment
and that the model can be applied to routine FFPE (-fixed
paraffin-embedded) tissue from initial diagnostic biopsies.
|
| Statins for patients with lymphoma?
 |
Statins Impair Antitumor Effects of Rituxan by Inducing
Conformational Changes of CD20
Statins were shown [in cell culture experiments] to
interfere with both detection of CD20 and antilymphoma
activity of rituximab. These studies have significant clinical
implications, as impaired binding of mAbs to conformational
epitopes of CD20 elicited by statins could delay diagnosis,
postpone effective treatment, or impair anti-lymphoma activity
of rituximab.
|
|
The Potential Effect of Statins on Rituxan Immunotherapy pubmedcentral.nih.gov
"Given the potential implications of these findings, the
next steps are to confirm them and then to establish the CD20
status of patients on long-term statin treatment. Subsequently, it
will be important to address whether equivalent effects on CD20
binding are observed in patients suffering from malignant or
autoimmune disease to determine whether B cells in these
conditions are more or less susceptible to the effects of
cholesterol depletion through statin treatment."
|
|
| Alert: Medicare 5-year cancer bill tops $21.1 bln: study reuters.com
"There were about 10 million Americans living with cancer in 2003. The National Cancer Institute has estimated that, overall, the United States spent $72.1 billion in 2004 in direct costs for cancer care."
|
| Fatigue: Physical Exercise May
Help Reduce Fatigue During and After Cancer Treatment Medscape
"Exercise appears to have some benefit in the management
of fatigue both during and after cancer treatment," the
reviewers conclude. "Therefore it should be considered as one
component of the management strategy for fatigue that may include
a range of other interventions and education. . . . Further work
is necessary to determine the most effective parameters of
exercise for fatigue management including the types of exercise
(aerobic and resistance), mode of exercise, frequency and length
of sessions, and intensity of exercise carried out."
|
| Encouragement: A message
for the newly diagnosed PAL
|
| HL trends: Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients.
Blood. 2008 Mar 15;111(6):2977-83. Epub 2007 Dec 20. PMID: 18096762
Our period analysis discloses ongoing, major improvement in
long-term survival of patients with HD in recent years,
particularly among older patients.
|
| Open Letter to SEER:
Regarding capturing statistics for lymphoma subtypes PAL
seerltr.pdf
The SEER website has improved, but the utility of the
statistics for non-Hodgkin's lymphomas continue to suffer because
subtypes of the disease are not yet provided.
 Make
your views known to SEER: http://seer.cancer.gov/about/contact.html
|
| Hoax email (Johns Hopkins) about cancer treatment and causes
cancerhelp.org.uk
I've been sent an email, which is really worrying me. I have cancer and
this says my treatment won't help and may even harm me. It's also made me
worry that heating foods in the microwave for my kids will give them
cancer - it says this information comes from an American University called
Johns Hopkins. Can you tell me if any of this is true?
|
| Secondary cancers: Risk Of
Second Cancers Greatest In Younger Patients Treated For
Non-Hodgkins Lymphoma medicalnewstoday.com
"The fact that tumour toll is largest 21 to 30 years after
diagnosis has important implications for the timing of medical
surveillance schemes for patients with NHL. "Longer follow-up
periods of patients will be needed to fully characterize the
long-term effects of NHL therapy," they write, adding the
individual solid tumours are likely to show variable responses."
|
| Preclinical: Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J Immunol. 2008 May 1;180(9):6392-401. PMID: 18424763
The results show, for the first time, that disruption of
inhibitory self-recognition can efficiently promote ADCC in a
human model, applying an autologous system in which physiologic
checkpoints are in place. This method provides an alternative
approach to potentiate the therapeutic benefit of antitumor Abs
that mediate ADCC.
|
| Risk factors: Non-Hodgkin
lymphoma risk increased by some autoimmune disorders medscape.com
The risk of NHL was increased 6.5-fold in patients with Sjgren
syndrome, 2.7-fold in patients with systemic lupus, and 2.6-fold
in patients with hemolytic anemia, the authors report
|
| Risk factors: Plasma donation associated with risk for non-Hodgkin's lymphoma
hemonctoday.com
Frequent plasma donors appeared to have a higher risk for
non-Hodgkin's lymphoma (>25 vs. 0 donations, OR 2.14). The
researchers concluded that this finding warrants additional
examination. – by Stacey L. Adams
Natl Cancer Inst.2008;100:1-8.
|
| fNHL outcomes: 8-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab.
Blood. 2008 Apr 14; PMID: 18411419
Forty-seven patients were included. All patients experienced
complete remission, with only 2 relapses. With a median follow-up
time of 60 months (range, 19-94), the estimated survival and
progression-free survival rates were 85% and 83%, respectively.
|
| CNS outcomes: Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie
Cellulaire. J Clin Oncol. 2008 Apr 14; PMID: 18413641
The respective median progression-free survival (PFS) times
after IC + HCR were 11.6 and 41.1 months. The 2-year overall
survival probability was 45% in the whole population and 69% among
the 27 patients who received IC + HCR. The 2-year PFS probability
was 43% among all the patients and 58% in the IC + HCR
subpopulation. CONCLUSION: IC + HCR is an effective treatment for
refractory and recurrent PCNSL.
|
| Technical background: Bone-marrow haematopoietic-stem-cell niches, Anne Wilson and Andreas Trumpp
nature.com PDF
|
|
fNHL outcomes: Dr. Ronald Levy,
LB-204: Results of a Phase III trial evaluating safety and
efficacy of idiotype vaccine, compared to non-specific
immunotherapy. AACR
Webcast
|
|
fNHL outcomes: Preliminary
results of a Phase I study of AME-133v, an Fc-engineered humanized
monoclonal antibody, in low-affinity Fc?RIIIa patients with
previously-treated follicular lymphoma: LB-70
http://www.acor.org/news/display.html?id=6643
(scroll down to article)
AME-133v is a second-generation therapy that is believed to be
a more specific treatment for follicular lymphoma in general,
compared to rituximab, but is also thought to offer particular
benefits for those patients who have a variant in the immune cells
needed to attack the cancer, Forero says.
|
|
Preclinical
Non-invasive Targeted Radiofrequency Cancer Treatment
Destroying Cancer Cells with Radio Waves kanziuscancerresearch.com/
"The treatment concept: ... a “targeting molecule”
(antibody) is designed that will seek out and attach to or
penetrate through that unique site, the targeting molecule is
chemically attached to a gold nanoparticle or carbon nanotube, and
the combination is injected into the bloodstream of the patient.
The targeting molecule(s) eventually delivers the nanoparticle(s)
to the cancer cell(s). It is particularly exciting that metastatic
cancer cells might also be targeted. Exposure of the area to the
radiowaves causes the nanoparticles to warm sufficiently to kill
the cancer cells. This will require an extensive research effort,
especially to be able to ultimately treat the variety of cancers
potentially susceptible to this treatment approach."
|
|
New cd20 Mab: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial.
Blood. 2008 Apr 4; PMID: 18390837
| Related
articles
Clinical response rates ranged from 20-63%. Median time to
progression (TTP) for all patients/responders were 8.8/32.6 months
and median duration of response was 29.9 months at a
median/maximum follow-up of 9.2/38.6 months. Ofatumumab is
currently being evaluated in patients with rituximab-refractory
FL. This trial was registered at www.clinicaltrials.gov
NCT00092274.
|
|
Clinical trials: White
Paper on the Shortcomings of How Clinical Trials are Designed,
Carried Out and Funded in the U.S. EDICT
But while the need for clinical research is undisputed, how
clinical trials are now conducted remains problematic. Increasing
research finds major deficiencies in the way clinical trials are
designed, carried out and funded in the U.S. with serious
implications for the outcomes of medical research studies.
|
| Life style:
Smoking, drinking imperil lymphoma survival reuters.com
The results should strongly encourage patients with NHL "to stop smoking and lower alcohol consumption in order to obtain a general health benefit and improvements in the course of treatment," Talamini advised.
|
| Case report: Cutaneous follicular center B-cell lymphoma treated with intralesional
rituximab.
Actas Dermosifiliogr. 2008 May;99(4):291-6. Spanish. PMID: 18394405
| Related
articles
We also review the published cases of cutaneous B-cell lymphoma
treated with intralesional rituximab.
|
| Outcomes: Summary of MyVax
Personalized Immunotherapy Phase 3 Clinical Trial Results media.corporate-ir.net
pdf
"Genitope believes that the failure of its MyVax Phase 3
clinical trial to meet its primary endpoint was due to
unrecognized activity in the non-specific immunotherapy."
|
| QOL: Long-Term and Late Effects of Treatment in Adults
leukemia-lymphoma.org
pdf
No. 22 in a series providing the latest information for patients, caregivers
and healthcare professionals
|
| Identify patients with high-risk fNHL:
Predicting outcome in follicular lymphoma by using interactive gene pairs.
Clin Cancer Res. 2008 Jan 15;14(2):478-87. PMID: 18223222
The evidence reported here may provide the basis for an
expression-based, multi-gene test for predicting poor follicular
lymphoma outcomes.
|
| Assessing response to treatment early:
Diffusion MRI shown to give early signs of cancer's response to
treatment cancer.med.umich.edu
In the first study of its kind, researchers from the
University of Michigan Comprehensive Cancer Center are reporting
success in analyzing diffusion MRI images to distinguish between
dead and living brain tumor cells in both animals and humans. They
report that the imaging technique, which tracks the movement of
water through and between cells, allowed them to assess the effect
of therapy on the cancer without relying on measurable changes in
tumor size.
Clinical Trial: http://clinicaltrials.gov/ct2/show/NCT00645359
|
| HL risk factor: USC researchers
find new clues to risk of Hodgkin lymphoma genengnews.com
A long-term study of twins has led University of Southern
California (USC) researchers to find potential links between
Hodgkin lymphoma and levels of an immune response protein
(interleukin-12).
|
| Preventing / managing oral mucositis
(resources) - common and serious side effect related to high dose
therapy and stem cell transplantation Abstract
|
| Review: Lenalidomide for the treatment of B-cell malignancies.
J Clin Oncol. 2008 Mar 20;26(9):1544-52. Epub 2008 Feb 19. Review.
PMID: 18285605
"Its antitumor activity seems mediated through modulation
of both the cytokine and cellular tumor cell microenvironment.
Preclinical as well as clinical observations demonstrate that
lenalidomide downregulates production of various critical
prosurvival cytokines in the tumor microenvironment while
concurrently promoting activation of T- and natural killer (NK)
cell-mediated antitumor response. ... Consequently, the role
of lenalidomide in other B-cell malignancies has been
investigated, with impressive results in chronic lymphocytic
leukemia and non-Hodgkin's lymphoma. This review summarizes the
data from various clinical investigations and highlights the
impact of lenalidomide in the management of patients with B-cell
malignancies."
|
| Perspective:
How Quackery Harms Cancer Patients quackwatch.com
There is an old saying: "The highwayman demands
'your money OR your life,' but quacks demand 'your money AND your
life!'" This statement is particularly true when it comes to
dubious cancer treatment. The harm done by quackery may be
categorized as economic, direct, indirect, psychological and
societal.
|
|
RIT usage: CHMP Recommends Positive Opinion For
Zevalin, In First Line Consolidation Therapy For Follicular Lymphoma
http://www.medicalnewstoday.com/articles/101670.php
The recommendation is based on data from the First-line
Indolent Trial (FIT) study. The FIT study shows nearly a 2 year
improvement in progression free survival (PFS) in patients with
advanced follicular lymphoma receiving [90Y]-ibritumomab tiuxetan
vs, induction chemotherapy alone.1
|
|
Alert: Statins [commonly
prescribed drug] Impair Antitumor Effects of Rituxan by
Inducing Conformational Changes of CD20
medicine.plosjournals.org/
Statins were shown to interfere with both detection of CD20 and antilymphoma activity of rituximab. These studies have significant clinical implications, as impaired binding of mAbs to conformational epitopes of CD20 elicited by statins could delay diagnosis, postpone effective treatment, or impair anti-lymphoma activity of rituximab.
|
|
|
| Sad news: Page
Irby's personal fight with lymphoma ended on March 11, 2008, but
not her legacy
Page was and will remain an inspiration to me in her approach to life. As you may know, she was committed to helping others to navigate the medical system and was an articulate advocate for becoming an informed and proactive patient.
|
| Case report on safety:
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
Am J Hematol. 2008 Feb 15; PMID: 18335564
|
| Bad news:
Genitope halts MyVax work, examines future bizjournals.com
... said it will suspend work on its cornerstone personalized
cancer vaccine, MyVax, for follicular non-Hodgkin's lymphoma.
Also see our commentary
|
| Allo versus Auto SCT:
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Br J Haematol. 2008 Mar 3 PMID: 18318762
| Related
articles
|
| CNS outcomes: Primary central nervous system lymphoma:
mono-center, long-term, intent-to-treat analysis.
Cancer. 2008 Mar 4; PMID: 18318432
| Related
articles
Promising long-term results could be achieved with HDMTX-based
chemotherapy in patients with PCNSL in this monocenter study. The
MSKCC score proved useful for predicting survival.
|
| MRI imaging: Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma.
Br J Haematol. 2008 Apr;141(1):60-8. PMID: 18324967
MRI is probably sufficiently sensitive to rule out bone marrow
involvement in patients with malignant lymphoma. However, a
well-designed study with a large sample size is needed to confirm
current results.
|
| New study of
interest:
|
| Secondary treatment
risks: Liver dysfunction after chemotherapy in lymphoma
patients infected with hepatitis C blackwell-synergy.com
... "baseline screening for HBV and HCV before initiation
of chemotherapy is crucial. High-risk patients having chronic
active hepatitis, high baseline HCV viral load, HBV co-infection
and receiving cytotoxic drugs, corticosteroids and rituximab
(particularly if combined) should be closely monitored for serum
transaminase, bilirubin and HCV RNA levels."
|
| Drug development: Traditional Medicine: Identifying Potential Cancer Treatments Of Herbal Origin
http://www.sciencedaily.com
ScienceDaily (Mar. 5, 2008) — Curing cancer with natural products -- a case for shamans and herbalists? Not at all, for many chemotherapies to fight cancer applied in modern medicine are natural products or were developed on the basis of natural substances. Thus, taxanes used in prostate and breast cancer treatment are made from yew trees.
The popular periwinkle plant, which grows along the ground of many front yards, is the source of vinca alkaloids that are effective, for example, against malignant lymphomas.
The modern anti-cancer drugs topotecan and irinotecan are derived from a constituent of the Chinese Happy Tree.
|
| DLBCL Outcomes:
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
prnewswire.com:
In this study, 20 previously untreated elderly patients were
treated with a novel combination of six cycles of CHOP
chemotherapy followed by Zevalin given six to ten weeks later.
|
| MCL outcomes
report: Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.
Leuk Lymphoma. 2008 Mar;49(3):447-50. PMID: 18297520
Eighty-two percent achieved an objective response with 46%
complete responses and 36% partial responses. Median time on
therapy was 17 months. The regimen was well tolerated. Our
findings demonstrate that low-dose oral agents administered in
combination for continuous, prolonged periods with minimal
drug-free intervals (metronomic therapy) may represent a novel,
effective, easily tolerated approach to MCL and that this
treatment approach warrants further exploration.
|
| Association: Prognostic influence of tumor-infiltrating mast cells in follicular lymphoma patients treated with rituximab and CHOP.
Blood. 2008 Feb 28; PMID: 18309035
... the data demonstrate that high MC (tumor-associated
mast cells) score is associated with unfavorable prognosis and it
eliminates the positive prognostic value of TAMs (tumor associated
macrophage) in FL patients treated with immunochemotherapy.
|
| Early Prognostic: C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk Lymphoma. 2008 Mar;49(3):470-6.
PMID: 18297523
This is a small series but one which raises the possibility
that the presence of a C-MYC translocations at presentation may
identify a particularly aggressive subtype of FL. Further studies
are required to investigate the true incidence of this aberration,
the impact on C-MYC regulation, clinical course and response to
treatment.
|
| Newsy report:
low dose Radiotherapy + CpG immunotherapy: smh.com.au
Professor Ronald Levy, acclaimed cancer researcher and head of
the Division of Oncology at Stanford University, said the
radiotherapy killed cancer cells at the injection site, but the
stimulant triggered the immune system to track and exterminate
deadly cells elsewhere in the body.
"Of the 13 patients in the pilot study, four are in
remission," Prof Levy said.
|
| Quality of life: Expressive
Writing Appears To Change Thoughts And Feelings About Cancer http://www.medicalnewstoday.com:80/articles/98355.php
49 percent of participants who completed the writing exercise
reported that writing changed their thoughts about their illness,
while 35 percent reported writing changed they way they felt about
their illness. At the three week follow-up, 54 percent of those
completing all parts of the study reported writing changed their
thoughts and 38 percent reported writing changed their feelings
about their illness. Two factors -- younger age, and less time
since diagnosis, were associated with more change in thoughts and
feelings.
|
| Future target for
therapy? B Cell Mutations That May
Cause Cancers And
Autoimmune Diseases medicalnewstoday.com/
Dr Brink believes his team has uncovered an important clue as
to how these diseases may be treated in the future. "When we
examined the genes expressed in the long-lived B cells, we noticed
that mutations in the TRAF2 or TRAF3 gene cause major changes to
other genes within the B cell. We found around 20 genes whose
expression went up dramatically in these cells.
|
| Preclinical
immunotherapy: Novel Way To Develop Tumor Vaccines:
Regulate Immune Inhibitor To
Overcome Tumor Suppression sciencedaily.com/
The study identified a new molecular player called A20, an
enzyme that restricts inflammatory signal transduction in
dendritic cells. When it is inhibited, the dendritic cells
overproduce an array of cytokines and co-stimulatory molecules
that triggers unusually strong immune responses that cannot be
suppressed by regulatory T cells. The resulting hyperactivated
immune responses triggered by A20-deficient dendritic cells are
capable of destroying various types of tumors that are resistant
to current tumor vaccines in mice.
|
| Clinical trial
participation: Most Cancer
Patients Satisfied With Clinical Trial Experience,
Yet Few Aware of
Opportunity foxcentraloregon.com/
The survey determined that only 10 percent of the 1,788 cancer
survivors knew participation in a cancer clinical trial was an
option. Of those who learned about trials, 73 percent cited their
physician as the source of information. The participants' type of
cancer influenced their awareness, as did type of treatment.
"One of the most important steps a patient can take to regain
some control when faced with a cancer diagnosis is to be as
informed as possible about his or her disease," said Dr.
Miller. "It was encouraging to find that most patients would
be inclined to participate if enrollment in a clinical trial was
presented as a treatment option."
|
| Infection-driven?
Eliminating Infection at Diagnosis of Slow-growing NHL May Be
Important Treatment Step cancerconsultants.com:
It appears that indolent NHL in patients with an infection may
have a different biology from indolent NHL in patients without an
infection, as evidenced by the differences in time required for
NHL therapy. As well, it appears that antimicrobial therapy may
provide benefit for some patients with indolent NHL and an
infection. Although this topic needs further study, these results
provide provocative data that may lead to different treatment
strategies in NHL.
|
|
|
| The Big
picture: Battling the Hematological Malignancies: The 200 Years' War
Full article http://theoncologist.alphamedpress.org/cgi/content/full/13/2/126
The delineation of the hematological malignancies began near the end
of the first third of the 19th century ... These challenges will be gradually overcome, if we (a) develop new
models of cooperation among academia, industry, and government
[and patients], (b) continue the growth of international participation in cancer research
(more keen minds to the task), and (c) convince the governments of the
world, including that of the U.S., that an investment in minimizing
the effects of cancer is as important as defending against other threats to the welfare and longevity of their citizens.
|
| Education: Spotlight on New Discoveries in NHL:
leukemia-lymphoma.org
Update from the American Society of Hematoloty (ASH) Annual Meeting
This program featured Wyndham Wilson, M.D., Ph.D, senior investigator, head, Lymphoma Therapeutics Section, National Cancer Institute, Bethesda, MD.
|
| Updated
Clinical Practice Guidelines for Oncologists: nccn.org
pdf 2008
Technical guidance for treatments of lymphomas by type.
|
|
|
| Review:
Zevalin in Mantle Cell Lymphoma touchbriefings.com
pdf 2007
Conclusion: Radiotherapy is an active treatment modality in
MCL. Ibritumomab radioimmunotherapy (Zevalin) is an interesting
alternative to other consolidation methods. In younger patients
subjected to intensive chemotherapy followed by autologous
transplant, it may be an element of a transplant conditioning
regimen (i.e. Z-BEAM). In elderly patients, the role of zevalin
consolidation should be further investigated in a phase III trial.
|
| CLL Outcomes: Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy
in patients with Richter's syndrome or fludarabine-refractory CLL.
J Clin Oncol. 2008 Jan 10;26(2):196-203. PMID: 18182662
The OFAR regimen is highly active in RS and has activity in
fludarabine-refractory patients with CLL. This regimen warrants
further investigation in the treatment of these disorders.
|
| Risk factors for development of a second lymphoid malignancy in patients with
CLL.
Br J Haematol. 2007 Nov;139(3):398-404. PMID: 17910629
|
| Preclinical: AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Blood. 2008 Feb 21; PMID: 18292288
Over-expression of anti-apoptotic members of the Bcl-2 family
are observed in approximately 80% of B-cell lymphomas,
contributing to intrinsic and acquired drug resistance. Nullifying
anti-apoptotic function can potentially overcome this intrinsic
and acquired drug resistance. ... The addition of AT-101 to
cyclophosphamide (Cy) and rituximab (R) in a schedule-dependent
manner enhanced the efficacy of the conventional therapy [ in cell
culture and animal models].
Clinical
trials with AT-101
|
| AITL Prognostic
factors: Clinical, biological and pathological features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
Blood. 2008 Feb 21; PMID: 18292286
"In multivariate analysis, only male gender (p=0.004),
mediastinal lymphadenopathy (p=0.041) and anemia (p=0.042)
adversely affected overall survival.
... In conclusion, AITL is a morphologically heterogeneous T-cell
lymphoma commonly expressing CXCL13 and CD10 and carrying few
prognostic factors. It portends a poor prognosis even when treated
intensively. However, not always lethal as 30% of patients are
alive at 7 years."
|
| Quality of life: Post-traumatic
stress (PTS) outcomes in NHL survivors. ncbi.nlm.nih.gov
| About Post Traumatic
Stress Disorder http://www.medicinenet.com
"Posttraumatic stress disorder (PTSD) is an emotional
illness that develops as a result of a terribly frightening,
life-threatening, or otherwise highly unsafe experience. PTSD
sufferers re-experience the traumatic event or events in some
way, tend to avoid places, people, or other things that remind
them of the event (avoidance), and are exquisitely sensitive
to normal life experiences (hyperarousal). "
|
|
| More ... Archive
2006/7
|
